anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
PURPOSE:To obtain the title new compound useful as an intermediate for a new cephem compound suitable as an excellent medicine having antitumor action. CONSTITUTION:A compound shown by formula I {R<11> is lower alkanoyl or group shown by formula II [R<5> is (protected) amino; R<6> is H or organic group which may contain substituent group]; R<3> is (protected) carboxy; Y2 is acid residue} and a salt thereof. The compound shown by formula I, for example, includes benzhydryl 7-amino-3mesyloxy-3-cephem-4-carboxylate. The compound shown by formula I is obtained by reacting a compound shown by formula III, its reactive derivative at the amino group or its salt with a compound shown by formula IV, its reactive derivative at the carboxy group or its salt. A compound shown by formula V (R<1> is amino or acylamino; R<2> is H or aryl which may contain substituent group, etc.) is obtained by reacting the compound shown by formula I with a compound shown by formula VI or its salt. For example, benzhydryl 7-[2-allyloxyimino-2-(5-amino-1,2,4thiosdiazol-3-yl) acetamido]-3-mesyloxy-3-cephem-4-carboxylate (syn isomer) may be cited as the compound shown by formula V.
A nucleic acid encoding a mosaic hepatitis E virus (HEV) polypeptide, consisting of the nucleotide sequence defined in the Sequence Listing as SEQ ID NO:1 is provided. A nucleic acid encoding epitopes 5, 6, 22, 23, 24, 28 and 29 of hepatitis E virus and substantially lacking the nucleic acids intervening the epitope-coding nucleic acids in the native hepatitis E virus is also provided. An isolated nucleic acid that selectively hybridizes under stringent conditions with the mosaic polypeptide-encoding nucleic acid and has at least 70 % sequence identity with SEQ ID NO:1 is provided. Also provided are such nucleic acids having at least 80 %, 90 % and 95 % sequence identity. A polypeptide consisting essentially of the amino acid sequence defined in the Sequence Listing as SEQ ID NO:2 is provided. Polypeptides encoded by the present selectively hybridizing nucleic acids, and nucleic acids encoding epitopes 5, 6, 22, 23, 24, 28 and 29 of HEV and substantially lacking the nucleic acids intervening the epitope-coding nucleic acids are also provided.
Apparently healthy children at Year 1 to Year 6 in the primary school in Taiwan. Exclusion criteria are children with metal implant or splint, pacemaker implantation, limb defect or injury and pregnant.
BACKGROUND: Although progress has been made in the treatment of LAUD, the survival rate for patients remains poor. An in-depth grasp of the molecular pathways implicated in LUAD progression is vital for improving diagnosis and treatment strategies. This study aims to explore novel molecular mechanisms driving LUAD progression and identify new potential prognostic biomarkers for LAUD patients.
METHODS: Based on mass spectrometry analysis of human LUAD tissues, HNRNPD and MAD2L2 were identified as potential key proteins involved in LUAD progression. Subsequently, the interplay between HNRNPD and MAD2L2 was examined through dual-luciferase reporter assays, RNA-seq analysis, and various molecular biology techniques. Ultimately, the role of the HNRNPD/MAD2L2 axis in LUAD advancement and its potential as a prognostic indicator were investigated utilizing LUAD specimens, cell lines, and xenograft mouse models.
RESULTS: In human LAUD tissues and cell lines, elevated levels of HNRNPD and MAD2L2 proteins were discovered. It was determined that HNRNPD binds to the MAD2L2 promoter, forming a regulatory axis at the transcriptional level. Subsequently, both in vitro and in vivo data demonstrated that the downregulation of the HNRNPD/MAD2L2 axis inhibited LUAD progression, while this effect could be rescued by MAD2L2 upregulation. Conversely, the upregulation of the HNRNPD/MAD2L2 axis facilitated LUAD progression, and this outcome could be reversed by MAD2L2 knockdown. Mechanistically, the downregulation of HNRNPD suppressed the promoter activity and transcription of MAD2L2, thus inhibiting the PI3K/HIF1α/ANGPTL4 pathway and tumor angiogenesis. Finally, it was confirmed that LUAD patients with high levels of both HNRNPD and MAD2L2 exhibited the poorest prognosis. Therefore, the HNRNPD/MAD2L2 axis has been identified as a potential predictive indicator for LUAD patients.
CONCLUSIONS: The HNRNPD/MAD2L2 axis facilitates LUAD progression and serves as a potential prognostic biomarker.
INTRODUCTION: Anterolateral cordotomy (AL-C) is a long-established treatment for alleviating intractable cancer pain. However, AL-C has progressively fallen into desuetude, leading to the risk of a definitive loss of expertise within neurosurgical teams. Our objective was therefore to provide an update on percutaneous and open AL-C, with special emphasis on contemporary operative technique.
MATERIAL AND METHODS: Patient selection, indications, outcomes and up-to-date operative technique are reviewed through illustrative cases, including intraoperative photographs and video.
RESULTS: Main indications are represented by unilateral, nociceptive pain refractory to best pharmacological treatment in patients with limited life expectancy. Percutaneous AL-C is performed under cooperative sedation at C1-C2 level. CT myelography guidance and intraoperative electrophysiology allow accurate targeting of the spinothalamic tract (STT). Thermocoagulation is performed at 80 °C for 60 s during a Mingazzini maneuver, in order to promptly detect the potential onset of a motor weakness. Open AL-C is performed under general anesthesia at T2-T3 level. The dentate ligament is suspended to gently rotate the spinal cord and expose the anterolateral column. Section of the STT is made with a micro scalpel blade at a depth of 4-5 mm, from the dentate ligament to the emergence of ventral rootlets. Success rate after AL-C is high and allows a marked reduction in antalgic drugs intake. Main limitations include failure in achieving long-standing pain relief and the new occurrence of spontaneous, mirror pain.
CONCLUSION: AL-C is a safe and effective option for the management of opioid-resistant cancer pain, which should be part of the neurosurgeon's armamentarium.
An array of at least two commonly-branded absorbent articles, such as wipes products. The array includes a first wipes product and a second wipes product. Each wipes product may appeal to a different type of consumer, such as a light experience seeking consumer and a heavy experience seeking consumer. The first wipes product may include a first supply of wipes formed from a first substrate. The first supply of wipes is moistened with a first functional lotion composition including a first fragrance accord and a first lotion formula. The second wipes product may include a second supply of wipes formed from a second substrate. The second supply of wipes is moistened with a second functional lotion composition including a second fragrance accord and a second lotion formula. The second fragrance accord is different from the first fragrance accord, and the second lotion formula is different from the first lotion formula.
The present invention relates to the field of pharmaceutical chemistry. Disclosed are an acid amide compound and use thereof in the treatment of cancers. Disclosed is use of an acid amide compound represented by formula (I), or its crystalline form, or its stereoisomer, or its isotopologue, or its tautomer, or its pharmaceutically acceptable salt, or its solvate, or its prodrug, or its metabolite in the treatment of cancers. The experimental results show that the present compound can inhibit the proliferation of prostate cancer cells, and in particular, has an obvious inhibition effect on a drug-resistant prostate cancer cell line (22RV1). In addition, the present compound can also significantly inhibit the proliferation of various cancer cells. Furthermore, the present compound has good pharmacokinetics, and has a potential treatment effect on cancers, in particular, prostate cancer, and provides a new option for clinically screening and/or preparing cancer drugs.
<P>PROBLEM TO BE SOLVED: To obtain a thickening stabilizer providing high operation efficiency in a food production process by paying attention to a material modifying properties of a food.  <P>SOLUTION: This thickening stabilizer contains a sesame extract (e.g. water extract of degreased pasty sesame). An aqueous solution of the sesame extract and a xanthan gum reveals that the aqueous solution has values of a storage elastic modulus (G') and a loss tangent (tanδ) nearer to those of an aqueous solution of a Locust bean gum and the xanthan gum than those of an aqueous solution of the xanthan gun and sucrose in a sol shape, and is determined that the aqueous solution forms a hard gel from the measured results of dynamic viscoelasticity of the aqueous solution of the sesame extract and the xanthan gum, the aqueous solution of the Locust bean gum and the xanthan gum, and the aqueous solution of the the xanthan gum and sucrose. The viscosity of the aqueous solution of the sesame extract is nearly same to that of the aqueous solution of the sucrose, and very low compared to thickening polysaccharides such as the Locust bean gum.  <P>COPYRIGHT: (C)2005,JPO&NCIPI
The genomic structure including the sequence of the intron/exon junctions is disclosed for KVLQT1 and KCNE1 which are genes associated with long QT syndrome. Additional sequence data for the two genes are also disclosed. Also disclosed are newly found mutations in KVLQT1 which result in long QT syndrome. The intron/exon junction sequence data allow for the design of primer pairs to amplify and sequence across all of the exons of the two genes. This can be used to screen persons for the presence of mutations which cause long QT syndrome. Assays can be performed to screen persons for the presence of mutations in either the DNA or proteins. The DNA and proteins may also be used in assays to screen for drugs which will be useful in treating or preventing the occurrence of long QT syndrome.
The purpose of the current study is to further develop the integrated Eating Aversion Treatment (iEAT) manual and address the unmet needs of many children with chronic food refusal by providing a technology-based treatment that makes it easy for parents to understand how to duplicate the models of institutional care. The study seeks to expand upon this treatment by introducing the manual and procedures in an electronic form to be implemented by caregivers in a home environment.

The study team aims to enroll 20 participants with chronic food refusal and formula or feeding tube dependence. Participants will be randomly assigned to receive the iEAT manual intervention with the technology supported manual or a control group (10 participants per group). The intervention with the iEAT manual will involve 10 biweekly outpatient appointments of about 45 minutes in length. Target behaviors will be assessed during each treatment meal. Participants will be assessed pre-treatment and at a one month follow-up to assess long term effects. Parents in the control group will provide a food diary once a month, for 5 months. Those assigned to the control group will be able to cross-over to receive the iEAT treatment manual following completion of post-study measures. Screening, collecting data for outcomes measures, and the intervention will be conducted at the each participant's home. Data will be collected on parent compliance with the treatment manual and child food acceptance, nutritional intake, and refusal behaviors.
PURPOSE:To provide the titled tea containing the fruit of wax gourd and leaf of tea as essential components. CONSTITUTION:The fruit of wax gourd (a plant of Cucurbitaceae family) is sterilized and the seeds are removed therefrom. The fruit is freeze-dried, spray- dried or dried after extracting with an aqueous solvent to obtain powdery wax gourd. 1-2pts. of fermented tea leaves are mixed with 1pt. of the powdery wax gourd to obtain the objective food good for health of the eye. The food is further compounded preferably with the flour of chrysanthemum (a plant of Compositae family), tangle, Panax ginseng (whole grass), etc. The mixture may be packed in a bag. A proper amount of the mixture is dissolved in hot water and sugared with desired amount of sweetener or the mixture is served in the form of a tea-bag. EFFECT:The product emits unique flavor and has soft sweetness. The component of fruit can be transferred easily to the tea with hot water, and the food is effective to activate the cells and promote the blood flow by the saponin component existing in the fruit of wax gourd.
PURPOSE: A method for extracting anthocyanin is provided to control temperature and pressure conditions to maintain anthocyanin functionality and to be used for various industrial fields as food, pharmaceutical, and cosmetic materials. CONSTITUTION: A supercritical extraction method for extracting anthocyanin ingredients from black soybean powder comprises a step of extracting while stirring carbon dioxide of a supercritical state using water and alcohol under an acidic condition. The supercritical state is a temperature of 30-60 deg. C and a pressure of 80-300 bar. An apparatus for extracting anthocyanin comprises a cooler(120), a high pressure liquid pump(130), a reactor(180), a primary separation tank(200), and a secondary separation tank(230). The cooler changes a phase into a liquid phase by cooling carbon dioxide from CO_2 container(100). The high pressure liquid pump receives and pressurizes carbon dioxide. The reactor heats and stirs a reactant of the black soybean powder, water, ethanol, and organic acid in an inner receiving unit by mounting a magnetic driving device(170) for stirring and a heating device. The primary and secondary separation tanks separate carbon dioxide and the reactant by spraying the reactant to a low pressure container and has a filter(210).
GL-ONC1, an oncolytic vaccinia virus, has shown the ability to preferentially locate, colonize and destroy tumor cells in more than 40 different human tumors. A First-in-Man, Phase I clinical study focusing on the safety and tolerability of GL-ONC1 intravenously administered to patients with a variety of advanced solid tumor entities has shown that GL-ONC1 is well-tolerated at therapeutic dose levels, with documented evidence of antitumor activity. Preclinical studies have further shown synergistic effects with the use of chemotherapy (Cisplatin) and viral therapy with GL-ONC, as well as favorable results when cancer cells are irradiated and then treated with GL-ONC1 in animal models. This Phase I study seeks to evaluate the safety, tolerability and early signs of efficacy of GL-ONC1 administered intravenously in combination with standard of care (SOC) radiation therapy (RT) and cisplatin (CDDP)in patients with locoregionally advanced head and neck cancer. Patients will be individually assessed for safety and dose limiting toxicity. Viral colonization in tumors, replication and anti-tumoral activity will also be evaluated.
INTRODUCTION: Superior and inferior ramus fractures, termed straddle fractures, are high-energy fractures often accompanied by unstable pelvic ring injuries. However, consensus is lacking regarding indications for surgical treatment or fixation methods. We aimed to compare clinical and radiological outcomes of unilateral ramus fixation (URF) and bilateral ramus fixation (BRF) for straddle fractures with unilateral posterior pelvic ring injuries.
MATERIALS AND METHODS: We enrolled 118 patients (73 males, 45 females; mean age, 47 years) diagnosed with straddle fractures between March 2015 and December 2021 with > 1 year of follow-up. Patients were divided into URF (n = 60) and BRF (n = 58) groups based on the anterior pelvic ring fixation method. Preoperative factors including body mass index, diabetes, smoking, injury mechanism, injury severity score, American Society of Anesthesiologists classification system, Tile classification, and Young and Burgess classification were compared. Intraoperative blood loss, operation time, postoperative bone union rate, complications, and the need for additional surgeries were analyzed.
RESULTS: There were no statistically significant preoperative differences between the two groups. However, the URF group showed a significantly lower mean operative time and blood transfusion requirement (63 min and 2 units, respectively) than the BRF group (104 min and 3 units, respectively) (both p < 0.001). Postoperatively, bone union was achieved in 57 (95.0%) and 56 (96.6%) patients in the URF and BRF groups, respectively. Complications occurred in 17 (28.3%) and 14 (24.1%) patients in the URF and BRF groups, respectively, with additional surgeries needed in 3 (5.0%) patients in the URF group and 2 (3.4%) patients in the BRF group.
CONCLUSIONS: Unilateral anterior fixation can provide sufficient stability and clinical effectiveness in the surgical treatment of straddle fractures in areas with posterior pelvic ring injuries. Compared with bilateral anterior fixation, unilateral fixation significantly reduces operation time and blood loss, making it a viable fixation method for straddle fractures.
The placebo group was taken orally until the end of week 12. At the end of week 12, the placebo group was switched to the oral administration of TQH3821 tablets 200 mg until the end of week 24.
Men/Women, ages 18-75 without a current diagnosis of asthma and no allergies. No intervention; this is a prospective observational study.
Participants in the PCT group will complete a PCT test within 2 hours after randomization and the results will be sent back to the clinician by laboratory through the internal network of the hospital. The prescribing clinician will use the results of the PCT to help guide their antibiotic prescription decision. The detailed recommendations are as follows: if PCT\<0.1ng/ml，strongly discouraged；if PCT (0.1-0.25ng/ml) and no sputum purulence, discouraged; if PCT (0.1-0.25ng/ml) and sputum purulence, Recommended; PCT\>0.25 ng/ml, Strongly recommended.
Androgenetic alopecia is a genetic disorder that commonly causes progressive hair loss in men, leading to diminished self-esteem. Although cannabinoids extracted from Cannabis sativa are used in hair loss treatments, no study has evaluated the effects of germinated hemp seed extract (GHSE) and exosomes derived from the calli of germinated hemp seeds on alopecia. Therefore, this study aimed to demonstrate their preventive effects against alopecia using various methodologies, including quantitative PCR, flow cytometry, ELISA, and immunocytochemistry. Our research highlights the preventive functions of GHSE (GE2000: 2000 µg/mL) and exosomes from the calli of germinated hemp seeds (E40: 40 μg/mL) in three biochemical categories: genetic modulation in hair follicle dermal papilla stem cells (HFDPSCs), cellular differentiation, and immune system modulation. Upon exposure to dihydrotestosterone (DT), both biomaterials upregulated genes preventing alopecia (Wnt, β-catenin, and TCF) in HFDPSCs and suppressed genes activating alopecia (STAT1, 5α-reductase type 1, IL-15R). Additionally, they suppressed alopecia-related genes (NKG2DL, IL2-Rβ, JAK1, STAT1) in CD8+ T cells. Notably, E40 exhibited more pronounced effects compared to GE2000. Consequently, both E40 and GE2000 effectively mitigated DT-induced stress, activating mechanisms promoting hair formation. Given the limited research on alopecia using these materials, their pharmaceutical development promises significant economic and health benefits.
The aim of this study is to evaluate the safety and efficacy at 12 months after repair of small and medium ventral hernias using PVP™. All patients operated between March 2009 and February 2011 at the participating centers, will be evaluated and described. Patients will be evaluated by clinical investigation, questioning and ultrasound. The investigators' main focus will be the incidence of complications related to the use of the device, during the first year. Also the investigators look at recurrence rate at 12 months, occurrence of pain at 12 months and foreign body feeling. The trial can be seen as a quality control of a cohort of patients treated with an innovative mesh device. No sponsoring from the company J\&J will be asked or accepted.
ZORVOLEX (diclofenac) capsules are a nonsteroidal anti-inflammatory drug, available as hard gelatin capsules of 18 mg and 35 mg for oral administration. The chemical name is 2-[(2, 6-dichlorophenyl) amino] benzeneacetic acid. The molecular weight is 296.15. Its molecular formula is C14H11Cl2NO2, and it has the following chemical structure.

Diclofenac acid is a white to slight yellowish crystalline powder. Diclofenac acid has a pKa of 4.18 and a logP of 3.03. It is practically insoluble in water and sparingly soluble in ethanol. 

The inactive ingredients in ZORVOLEX include a combination of lactose monohydrate, sodium lauryl sulfate, microcrystalline cellulose, croscarmellose sodium and sodium stearyl fumarate. The capsule shells contain gelatin, titanium dioxide, and dyes FD&C blue #1, FD&C blue #2, FDA/E172 Yellow Iron Oxide and FDA/E172 Black Iron Oxide. The imprinting on the gelatin capsules is white edible ink. The 18 mg capsules have a blue body imprinted with IP-203 and light green cap imprinted with 18 mg in white ink. The 35 mg capsules have a blue body imprinted with IP-204 and green cap imprinted with 35 mg in white ink.
The invention features a method designed to lengthen the time an implanted organ (a xenograft) survives in a xenogeneic host prior to rejection. Preparation of the recipient for transplantation includes the following steps: First, the recipient is administered low dose radiation. Second, an antibody preparation that binds T cells and NK cells is injected into the recipient. Third, natural antibodies are absorbed from the recipient's blood by hemoperfusion of an organ of the donor species. Fourth, hematopoietic stromal tissue of the donor species is administered to the recipient. Fifth, donor hematopoietic stem cells are injected into the recipient. Finally, the xenograft organ is implanted into the recipient mammal. Best results are obtained when all steps are used in combination.
Fetal pericardial teratomas are rare. They present with pericardial effusion and hydrops. The definitive management is postnatal resection of the tumor. The exact antenatal management is not known due to its rarity. We present a case of fetal pericardial teratoma with pericardial tamponade. Pericardiocentesis performed at 31 weeks significantly relieved the venous compression, leading to resolution of hydrops and prolonging the gestational age for the definitive management.